OIPE VOISE FEB 0 1 2005 SE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	THE CIVILED ST	TILLO TILLETT.	AND HOLDE	WHICE OFFICE
U.S. Appln. Confirmation U.S. Filing I Title of Inve	of : Shirlynn Ch No. : 10/663,220 n No. : 2110 Date : 09/16/2003 ntion : Potent Inhib et No.: 9/260) Art Unit:) Examiner: ne Protease	1654 Andrew D. Kosar
P. O. Box 14	er for Patents			
February 3, 2	2005			
TRANSMI	TTAL LETTER F	OR SUPPLEME STATEM		MATION DISCLOSURE
Sir:				
				rmation Disclosure nore specifically described
§1.53 (d); ii) 37 C.F.R. §1. on the merits	onal application oth within three (3) mo 491 in an internatio	er than a continuenths of the date of the date of the date of all application; is alling of a first C	ed prosecution ap f entry of the nat ii) before the ma	e (3) months of the filing oplication under 33 C.F.R. ional stage as set forth in iling of a first Office action the filing of a request for
C.F.R. §1.97(notice of allo	(b), but before the m	nailing date of: i) S.R. §1.311, or iii	a final action und an action that o	period specified in 37 der 37 C.F.R. §1.113, ii) a therwise closes prosecution
	A statement as sp	ecified in 37 C.F	.R. §1.97(e) [see	below]; or

The fee set forth in 37 C.F.R. §1.17(p).

The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).
1.97(e).
Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.
The fee set forth in 37 C.F.R. §1.17(p).
The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Philip I. Datlow

Attorney for Applicant(s)

Reg. No. 41,482

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4542 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on February 3, 2005

Philip I. Datlow, Reg. No. 41,482

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Repervork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				1		
Substitute for form 1449B/PTO				Complete If Known		
				Application Number	10/663,220	
INFORMATION DISCLOSURE				Filing Date	09/16/2003	
STATEMENT BY APPLICANT			CANT	First Named Inventor	Shirlynn CHEN	
				Art Unit	1654	
(Use as many sheets as necessary)				Examiner Name	Andrew D. Kosar	
Sheet	1	of	1	Attorney Docket Number	9/260	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
		LAMARRE et al., "An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus", Nature, vol. 426 (2003), pgs. 186-189			
		HINRICHSEN et al., "Short-term Antiviral Efficacy of BILN 2061, a Hepatatis C Virus Serine Protease Inhibitor, in Hepatitis C Genotype 1 Patients", Gastroenterology, vol. 127, no. 5 (2004), pgs. 1347-1355 			
•••••					
••••					
	••••••	-			
	•••••				

Date

Considered

Examiner

Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.